Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Chicago
Neonc Technologies, Inc.
ImmunityBio, Inc.
Ohio State University Comprehensive Cancer Center
Bristol-Myers Squibb
Incyte Corporation
Yale University
National Cancer Institute (NCI)